Genetic polymorphisms of the RAS-cytokine pathway and chronic kidney disease

Pediatric Nephrology

Volumn 23, Issue 7, 2008, Pages 1037-1051

  Wong, Craig ^a,d   Kanetsky, Peter ^b   Raj, Dominic ^c  

^a Division of Nephrology   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Cytokine; Genetic; Pediatric; Polymorphism; Progression

Indexed keywords

ANGIOTENSIN II; ANGIOTENSINOGEN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LYMPHOTOXIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SUBSTITUTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHILD HEALTH; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; GENE EXPRESSION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC ERROR;

ADULT; ANIMALS; CHILD; CHRONIC DISEASE; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; KIDNEY DISEASES; PHENOTYPE; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 44449170911     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-0816-z     Document Type: Review

References (139)

1. Wong CS, Furth SL (2007) Epidemiology of renal disease in children. In: Kher KK, Schnaper HW, Makker SP (eds) Clinical Pediatric Nephrology. Informa UK Ltd, London, pp 63-70
2. Wong CS, Mak RH (2007) Chronic kidney disease. In: Kher KK, Schnaper HW, Makker SP (eds) Clinical pediatric nephrology. Informa UK Ltd, London, pp 339-352
3. United States Renal Data System (2007) USRDS 2007 Annual Data Report: Atlas of chronic kidney disease and end stage renal disease in the United States. In: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD
4. NAPRTCS (2007) 2007 Annual Report. EMMES, Rockville, MD
5. Ardissino G, Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, Marra G, Edefonti A, Sereni F, ItalKid Project (2003) Epidemiology of chronic renal failure in children: Data from the ItalKid project. Pediatrics 111:e382-387
6. Soares CM, Oliveira EA, Diniz JS, Lima EM, Vasconcelos MM, Oliveira GR (2003) Predictive factors of progression of chronic renal insufficiency: a multivariate analysis. Pediatr Nephrol 18:371-377
7. Mitsnefes M, Ho PL, McEnery PT (2003) Hypertension and progression of chronic renal insufficiency in children: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 14:2618-2622
8. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O (1997) Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of nutritional treatment of chronic renal failure in childhood. Lancet 349:1117-1123
9. Seikaly MG, Ho PL, Emmett L, Fine RN, Tejani A (2003) Chronic renal insufficiency in children: The 2001 Annual Report of the NAPRTCS. Pediatr Nephrol 18:796-804
10. Eddy AA (2005) Progression in chronic kidney disease. Adv Chronic Kidney Dis 12:353-365
11. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J (2001) Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10:321-329
12. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305
13. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42:1050-1065
14. Meyer KB, Levey AS (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease; report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol 9:S31
15. Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191-197
16. Chavers BM, Li S, Collins AJ, Herzog CA (2002) Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 62:648
17. Merouani A, Lambert M, Delvin EE, Genest J Jr, Robitaille P, Rozen R (2001) Plasma homocysteine concentration in children with chronic renal failure. Pediatr Nephrol 16:805-811
18. Siirtola A, Antikainen M, Ala-Houhala M, Koivisto AM, Solakivi T, Jokela H, Lehtimaki T, Holmberg C, Salo MK (2004) Serum lipids in children 3 to 5 years after kidney, liver, and heart transplantation. Transpl Int 17:109-119
19. Saland JM, Ginsberg H, Fisher EA (2002) Dyslipidemia in pediatric renal disease: Epidemiology, pathophysiology, and management. Curr Opin Pediatr 14:197-204
20. Mitsnefes MM, Barletta GM, Dresner IG, Chand DH, Geary D, Lin JJ, Patel H (2006) Severe cardiac hypertrophy and long-term dialysis: The Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 21:1167-1170
21. Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2003) Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation 107:864-868
22. Mitsnefes MM (2002) Pediatric end-stage renal disease: Heart as a target. J Pediatr 141:162-164
23. Tsagalis G, Zerefos S, Zerefos N (2007) Cardiorenal syndrome at different stages of chronic kidney disease. Int J Artif Organs 30:564-576
24. Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, Raj DS (2007) Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 72:549-556
25. Ruiz-Ortega M, Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Carvajal G, Egido J (2006) Renal and vascular hypertension-induced inflammation: Role of angiotensin II. Curr Opin Nephrol Hypertens 15:159-166
26. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349:1857-1863
27. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945
28. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 139:244-252
29. Jacoby DS, Rader DJ (2003) Renin-angiotensin system and atherothrombotic disease: From genes to treatment. Arch Intern Med 163:1155-1164
30. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J (2002) Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl (82):12-22
31. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J, Ruiz-Ortega M (2004) Angiotensin II, via AT1 and AT2 receptors and NF-kappa B pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15:1514-1529
32. Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS (2000) Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappa B (NF-kappa B) transcription factor. Mol Cell Biochem 212:155-169
33. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J (2001) Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappa B and AP-1 in the kidney: Role of AT(1) and AT(2) receptors. Am J Pathol 158:1743-1756
34. Raj DS, Shah H, Shah VO, Ferrando A, Bankhurst A, Wolfe R, Zager PG (2003) Markers of inflammation, proteolysis, and apoptosis in ESRD. Am J Kidney Dis 42:1212-1220
35. Klahr S, Morrissey J (2003) Progression of chronic renal disease. Am J Kidney Dis 41:S3-S7
36. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: Recommendations from a pediatric nephrology panel established at the national kidney foundation conference of proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105:1242-1249
37. Drumm K, Bauer B, Freudinger R, Gekle M (2002) Albumin induces NF-kappa B expression in human proximal tubule-derived cells (IHKE-1). Cell Physiol Biochem 12:187-196
38. Zoja C, Benigni A, Remuzzi G (2004) Cellular responses to protein overload: Key event in renal disease progression. Curr Opin Nephrol Hypertens 13:31-37
39. Takase O, Marumo T, Imai N, Hirahashi J, Takayanagi A, Hishikawa K, Hayashi M, Shimizu N, Fujita T, Saruta T (2005) NF-kappa B-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int 68:464-473
40. Tarone G, Lembo G (2003) Molecular interplay between mechanical and humoral signalling in cardiac hypertrophy. Trends Mol Med 9:376-382
41. Lijnen P, Petrov V (1999) Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Methods Find Exp Clin Pharmacol 21:363-374
42. Dostal DE, Hunt RA, Kule CE, Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD, Baker KM (1997) Molecular mechanisms of angiotensin II in modulating cardiac function: Intracardiac effects and signal transduction pathways. J Mol Cell Cardiol 29:2893-2902
43. Lijnen P, Petrov V (1999) Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol 31:949-970
44. Murray DR, Prabhu SD, Chandrasekar B (2000) Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101:2338-2341
45. Petrov VV, Fagard RH, Lijnen PJ (2000) Transforming growth factor-beta(1) induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts. J Renin Angiotensin Aldosterone Syst 1:342-352
46. Park J-Y, Farrance IKG, Fenty NM, Hagberg JM, Roth SM, Mosser DM, Wang MQ, Jo H, Okazaki T, Brant SR, Brown MD (2007) NFKB1 promoter variation implicates shear-induced NOS3 gene expression and endothelial function in prehypertensives and stage I hypertensives. Am J Physiol Heart Circ Physiol 293:H2320-H2327
47. Balakrishnan VS, Guo D, Rao M, Jaber BL, Tighiouart H, Freeman RL, Huang C, King AJ, Pereira BJ (2004) Cytokine gene polymorphisms in hemodialysis patients: Association with comorbidity, functionality, and serum albumin. Kidney Int 65:1449-1460
48. Rao M, Jaber BL, Balakrishnan VS (2005) Gene polymorphism association studies in dialysis: Cardiovascular disease. Semin Dial 18:217-225
49. Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop P-H, Parving H-H, Cambien F, Tregouet DA, Gut IG, Theva A, Gauguier D, Farrall M, Cox R, Matsuda F, Lathrop M, Hager-Vionnet N, EURAGEDIC (European Rational Approach for Genetics of Diabetic Complications) Study Group (2007) Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: Case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol 18:1284-1291
50. Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, Bowden DW, Duggirala R, Elston RC, Hanson RL, Ipp E, Kao WH, Kimmel PL, Klag MJ, Knowler WC, Meoni LA, Nelson RG, Nicholas SB, Pahl MV, Parekh RS, Quade SR, Rich SS, Rotter JI, Scavini M, Schelling JR, Sedor JR, Sehgal AR, Shah VO, Smith MW, Taylor KD, Winkler CA, Zager PG, Freedman BI (2007) Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The family investigation of nephropathy and diabetes (FIND). Diabetes 56:1577-1585
51. Kim JA, Berliner JA, Nadler JL (1996) Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 226:862-868
52. Krejcy K, Eichler HG, Jilma B, Kapiotis S, Wolzt M, Zanaschka G, Gasic S, Schutz W, Wagner O (1996) Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. Can J Physiol Pharmacol 74:9-14
53. Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B (2005) Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54:1238-1244
54. Ng DP, Placha G, Choo S, Chia KS, Warram JH, Krolewski AS (2006) A disease haplotype for advanced nephropathy in type 2 diabetes at the ACE locus. Diabetes 55:2660-2663
55. Hohenfellner K, Wingen AM, Nauroth O, Wuhl E, Mehls O, Schaefer F (2001) Impact of ACE I/D gene polymorphism on congenital renal malformations. Pediatr Nephrol 16:356-361
56. Papp F, Friedman AL, Bereczki C, Haszon I, Kiss E, Endreffy E, Turi S (2003) Renin-angiotensin gene polymorphism in children with uremia and essential hypertension. Pediatr Nephrol 18:150-154
57. Haszon I, Friedman AL, Papp F, Bereczki C, Baji S, Bodrogi T, Karoly E, Endreffy E, Turi S (2002) ACE gene polymorphism and renal scarring in primary vesicoureteric reflux. Pediatr Nephrol 17:1027-1031
58. Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P (2001) Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int 60:46-54
59. Raizada V, Skipper B, Luo W, Garza L, Hines CW, Harford AA, Zager PG, Griffith J, Raj D, Spalding CT (2005) Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease. Kidney Int 68:1186-1189
60. Osono E, Kurihara S, Hayama N, Sakurai Y, Ohwada K, Onoda N, Takeuchi M, Tomizawa T, Komaba Y, Hashimoto K, Matsunobu S, Yoneshima H, Iino Y (1998) Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease. Am J Kidney Dis 32:725-730
61. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark AJ (1994) Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 330:1629-1633
62. Baudin B (2005) Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol 90:277-282
63. Renner W, Nauck M, Winkelmann BR, Hoffmann MM, Scharnagl H, Mayer V, Boehm BO, Marz W (2005) Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: The Ludwigshafen Risk and Cardiovascular Health Study. J Mol Med 83:235-239
64. Hsu CC, Bray MS, Kao WH, Pankow JS, Boerwinkle E, Coresh J (2006) Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study. J Am Soc Nephrol 17:504-512
65. Curnow KM, Pascoe L, White PC (1992) Genetic analysis of the human type-1 angiotensin II receptor. Mol Endocrinol 6:1113-1118
66. Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A (2006) Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant 21:979-983
67. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F (1994) Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24:63-69
68. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F, Ducimetiere P, Soubrier F, Camblen F (1994) Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 344:910-913
69. Arend WP (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13:323-340
70. Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 16:27-55
71. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA, Maseri A (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99:2079-2084
72. Balakrishnan VS, Jaber BL, Natov SN, Cendoroglo M, King AJ, Schmid CH, Pereira BJ (1998) Interleukin-1 receptor antagonist synthesis by peripheral blood mononuclear cells in hemodialysis patients. Kidney Int 54:2106-2112
73. Wetmore JB, Hung AM, Lovett DH, Sen S, Quershy O, Johansen KL (2005) Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney Int 68:278-284
74. Hurme M, Santtila S (1998) IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 28:2598-2602
75. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW (1993) Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91:403-404
76. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J (1992) A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 22:396-402
77. Huang G, Niu T, Peng S, Ling D, Liu J, Zhang X, Xu X (2004) Association between the interleukin-1beta C(-511)T polymorphism and blood pressure in a Chinese hypertensive population. Immunol Lett 91:159-162
78. Dewberry RM, Crossman DC, Francis SE (2003) Interleukin-1 receptor antagonist (IL-1RN) genotype modulates the replicative capacity of human endothelial cells. Circ Res 92:1285-1287
79. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC (1999) Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 99:861-866
80. Ray KK, Camp NJ, Bennett CE, Francis SE, Crossman DC (2002) Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. Clin Sci (Lond) 103:303-310
81. Watanabe M, Iwano M, Akai Y, Kurioka H, Nishitani Y, Harada K, Hamano K, Shiiki H (2002) Association of interleukin-1 receptor antagonist gene polymorphism with IgA nephropathy. Nephron 91:744-746
82. Amoli MM, Calvino MC, Garcia-Porrua C, Llorca J, Ollier WE, Gonzalez-Gay MA (2004) Interleukin 1beta gene polymorphism association with severe renal manifestations and renal sequelae in Henoch-Schonlein purpura. J Rheumatol 31:295-298
83. Buraczynska M, Ksiazek P, Kubit P, Zaluska W (2006) Interleukin-1 receptor antagonist gene polymorphism affects the progression of chronic renal failure. Cytokine 36:167-172
84. Chiappelli M, Tampieri C, Tumini E, Porcellini E, Caldarera CM, Nanni S, Branzi A, Lio D, Caruso M, Hoffmann E, Caruso C, Licastro F (2005) Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men. Int J Immunogenet 32:349-353
85. Sie MP, Sayed-Tabatabaei FA, Oei HH, Uitterlinden AG, Pols HA, Hofman A, van Duijn CM, Witteman JC (2006) Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: Results from the rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol 26:212-217
86. Losito A, Kalidas K, Santoni S, Jeffery S (2003) Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 64:616-622
87. Muller-Steinhardt M, Hartel C, Muller B, Kirchner H, Fricke L (2002) The interleukin-6 -174 promoter polymorphism is associated with long-term kidney allograft survival. Kidney Int 62:1824-1827
88. Girndt M, Ulrich C, Kaul H, Sester U, Sester M, Kohler H (2003) Uremia-associated immune defect: The IL-10-CRP axis. Kidney Int Suppl (84):S76-S79
89. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1-8
90. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW (1998) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 95:9465-9470
91. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S (1999) Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 277:F766-F772
92. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E (2000) Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101:2149-2153
93. Espinoza M, Aguilera A, Auxiliadora Bajo M, Codoceo R, Caravaca E, Cirugeda A, del Peso G, Hevia C, Selgas R (1999) Tumor necrosis factor alpha as a uremic toxin: Correlation with neuropathy, left ventricular hypertrophy, anemia, and hypertriglyceridemia in peritoneal dialysis patients. Adv Perit Dial 15:82-86
94. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M (2003) Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation 108:2317-2322
95. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 282:561-568
96. D'Alfonso S, Richiardi PM (1996) An intragenic polymorphism in the human tumor necrosis factor alpha (TNFA) chain-encoding gene. Immunogenetics 44:321-322
97. August P, Suthanthiran M (2006) Transforming growth factor beta signaling, vascular remodeling, and hypertension. N Engl J Med 354:2721-2723
98. Mezzano SA, Ruiz-Ortega M, Egido J (2001) Angiotensin II and renal fibrosis. Hypertension 38:635-638
99. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G (2002) How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J Am Soc Nephrol 13:2898-2908
100. August P, Suthanthiran M (2003) Transforming growth factor beta and progression of renal disease. Kidney Int Suppl (87):S99-S104
101. Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P (1999) TGF-beta 1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 33:271-275
102. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T (2002) TGF-beta 1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109:787-796
103. Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poirier O (1996) Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 28:881-887
104. Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P (2000) Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 97:3479-3484
105. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV (1998) Genotypic variation in the transforming growth factor-beta 1 gene: Association with transforming growth factor-beta 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66:1014-1020
106. Sato F, Narita I, Goto S, Kondo D, Saito N, Ajiro J, Saga D, Ogawa A, Kadomura M, Akiyama F, Kaneko Y, Ueno M, Sakatsume M, Gejyo F (2004) Transforming growth factor-beta 1 gene polymorphism modifies the histological and clinical manifestations in Japanese patients with IgA nephropathy. Tissue Antigens 64:35-42
107. Rao M, Guo D, Jaber BL, Tighiouart H, Pereira BJ, Balakrishnan VS (2004) Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int 66:419-427
108. Fogo AB (2000) The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 35:179-188
109. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB (2005) Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16:966-976
110. Francis CW (2002) Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 126:1401-1404
111. Reis K, Arinsoy T, Derici U, Gonen S, Bicik Z, Soylemezoglu O, Yasavul U, Hasanoglu E, Sindel S (2005) Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant 19:10-14
112. Wang AY, Poon P, Lai FM, Yu L, Choi PC, Lui SF, Li PK (2001) Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 59:1520-1528
113. Aucella F, Margaglione M, Vigilante M, Gatta G, Grandone E, Forcella M, Ktena M, De Min A, Salatino G, Procaccini DA, Stallone C (2003) PAI-1 4G/ 5G and ACE I/D gene polymorphisms and the occurrence of myocardial infarction in patients on intermittent dialysis. Nephrol Dial Transplant 18:1142-1146
114. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES (2001) High-resolution haplotype structure in the human genome. Nat Genet 29:229-232
115. Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR, Kautzer CR, Lee DH, Marjoribanks C, McDonough DP, Nguyen BT, Norris MC, Sheehan JB, Shen N, Stern D, Stokowski RP, Thomas DJ, Trulson MO, Vyas KR, Frazer KA, Fodor SP, Cox DR (2001) Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 294:1719-1723
116. The International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299-1320
117. Kruglyak L, Nickerson DA (2001) Variation is the spice of life. Nat Genet 27:234-236
118. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SC, Clayton DG, Todd JA (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29:233-237
119. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106-120
120. Check E (2007) Time runs short for HapMap. Nature 447:242-243
121. Wang WY, Barratt BJ, Clayton DG, Todd JA (2005) Genome-wide association studies: Theoretical and practical concerns. Nat Rev Genet 6:109-118
122. Healy DG (2006) Case-control studies in the genomic era: A clinician's guide. Lancet Neurol 5:701-707
123. Freimer NB, Sabatti C (2005) Guidelines for association studies in human molecular genetics. Hum Mol Genet 14:2481-2483
124. Rebbeck TR, Martinez ME, Sellers TA, Shields PG, Wild CP, Potter JD (2004) Genetic variation and cancer: Improving the environment for publication of association studies. Cancer Epidemiol Biomarkers Prev 13:1985-1986
125. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O'Brien TR, Rothman N, Stroup D, Taioli E, Thomas D, Vainio H, Wacholder S, Weinberg C (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156:300-310
126. Curtis D, Vine AE, Knight J (2007) A pragmatic suggestion for dealing with results for candidate genes obtained from genome wide association studies. BMC Genet 8:20
127. Pe'er I, de Bakker PI, Maller J, Yelensky R, Altshuler D, Daly MJ (2006) Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat Genet 38:663-667
128. Rothman KJ, Greenland S (2005) Causation and causal inference in epidemiology. Am J Public Health 95(Suppl 1):S144-S150
129. Vieland VJ (2001) The replication requirement. Nat Genet 29:244-245
130. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, Brooks LD, Cardon LR, Daly M, Donnelly P, Fraumeni JF, Freimer NB, Gerhard DS, Gunter C, Guttmacher AE, Guyer MS (2007) Replicating genotype-phenotype associations. Nature 447:655-660
131. Rebbeck TR, Khoury MJ, Potter JD (2007) Genetic Association Studies of Cancer: Where do we go from here. Cancer Epidemiol Biomarkers Prev 16:864-865
132. Ioannidis JP, Trikalinos TA, Khoury MJ (2006) Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 164:609-614
133. Cardon LR, Palmer LJ (2003) Population stratification and spurious allelic association. Lancet 361:598-604
134. Pompanon F, Bonin A, Bellemain E, Taberlet P (2005) Genotyping errors: causes, consequences and solutions. Nat Rev Genet 6:847-846
135. Terwilliger JD, Weiss KM (2003) Confounding, ascertainment bias, and the blind quest for a genetic "fountain of youth". Ann Med 35:532-544
136. Hennekens C, Buring J (1987) Case-control studies. Epidemiology in medicine. Little, Brown and Company, Boston, pp 132-152
137. Wacholder S, Rothman N, Caporaso N (2000) Population Stratification in Epidemiologic Studies of Common Genetic Variants and Cancer: Quantification of Bias. J Natl Cancer Inst 92:1151-1158
138. Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A, Warady BA (2006) Design and Methods of the Chronic Kidney Disease in Children (CKiD) Prospective Cohort Study. Clin J Am Soc Nephrol 1:1006-1015
139. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT (2003) The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. J Am Soc Nephrol 14:S148-153